ALBUQUERQUE, N.M., June 29, 2016 (GLOBE NEWSWIRE) -- Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed a testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced the formation of their scientific advisory board (SAB). Approved by the executive leadership team and board of directors, the SAB is chartered to advise on the development and commercialization of Mesa Biotech's infectious disease assay platform. Dr. Steve Young, of TriCore Reference Laboratories in Albuquerque, New Mexico, will lead a world class team with over 150 years of combined experience in infectious diseases and molecular point of care diagnostics.
Dr. Steve Young, Director of Research and clinical trials at TriCore Reference Laboratory has completed over 100 FDA in vitro diagnostic device trials/market evaluations. He is also diplomat of the American Board of Medical Microbiology and holds a Ph.D. from the University of New Mexico.
"We are thrilled to have such a talented and experienced scientific advisory board providing critical expertise to the Mesa Biotech team," said Hong Cai, co-founder and CEO. "The background and experience of our advisory board is going to be invaluable as we commercialize our current technology for the rapid, testing of influenza A/B, as well as to help us successfully reach our goal of bringing transformative diagnostics to the point of care."
Dr. Young said, "I am excited to be working alongside such an exceptionally talented group of doctors, researchers, and experts in the field of virology, pathology, microbiology and immunology. With this talented team of individuals we will help Mesa Biotech become a leader in the Point of Care Molecular diagnostic space".
About TriCore Reference Laboratories
TriCore Reference Laboratories is an independent clinical reference laboratory providing a complete range of services to health care professionals across the Southwest as well as pathology consultation services to clinicians across the country. TriCore also provides investigational services including FDA-regulated clinical trials, IRB-approved studies, device and diagnostic instrument testing, serving global biotech firms as well as academic clients. For more information, visit www.tricore.org
About Mesa Biotech Inc.
Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech's diagnostic system consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to obtain actionable, laboratory quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa's technology development has been funded to date by a series of grants and private equity investments totaling approximately $30 million. The company is preparing for Series A funding in 2016 and expects to obtain FDA approval for its first product, an influenza assay and dock, in 2017. For more information visit http://www.mesabiotech.com.
CONTACT: Carol Biondi Carol.firstname.lastname@example.org 505-379-5616
Source:TriCore Reference Laboratories